Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | DEFA14A: Others
Y-mAbs Therapeutics | DEF 14A: Definitive information statements
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Y-mAbs Therapeutics | 8-K: Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Current report
Y-mAbs Therapeutics | 8-K: Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
Y-mAbs Therapeutics | DEFA14A: Others
Y-mAbs Therapeutics | DEF 14A: Definitive proxy statements
No Data